Download PDF

1. Company Snapshot

1.a. Company Description

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada.The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services).It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.


The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others.In addition, it offers local and field-based customer support, as well as operates pump service and repair centers.The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Show Full description

1.b. Last Insights on INFU

InfuSystem Holdings, Inc.'s recent performance was driven by double-digit Patient Services revenue growth in Q1, fueled by diversification into wound care and biomedical services. The company's strategic partnerships and economies of scale have enabled recurring revenue and margin expansion. Additionally, InfuSystem's investments in integrated clinic-to-home healthcare solutions are starting to pay off, with record adjusted EBITDA margins achieved in Q1. The company's valuation remains attractive, trading at 5.4x FY25 EV/EBITDA, with limited tariff or economic cycle risk and moderate capital spending expected.

1.c. Company Highlights

2. InfuSystem Holdings' Solid FY25 Results Set Stage for Continued Growth

InfuSystem Holdings delivered a robust financial performance in FY25, with net revenue increasing by 7% to $36.2 million in the fourth quarter, and adjusted EBITDA expanding 17% to $8.8 million. The company's full-year adjusted EBITDA grew 24% to $31.5 million, while earnings per share (EPS) came in at $0.1, beating estimates of $0.07. The strong operating cash flow of $24.4 million, a 19% increase from the previous year, and a significant reduction in net debt by $6.9 million, demonstrate the company's ability to generate cash and deleverage its balance sheet.

Publication Date: 08:50

📋 Highlights
  • Top Line Growth & EBITDA Expansion: 7% Q4 revenue increase to $36.2M and 24% adjusted EBITDA rise to $31.5M for FY2025.
  • Balance Sheet Strengthening: 30% net debt reduction to $20M and $58M liquidity as of December 2025.
  • 2026 Growth Guidance: 6–8% pro forma revenue growth, with Patient Services driving 60%+ of total growth.
  • Cost Efficiency Gains: $2M annualized savings from ERP completion and $2M gross margin improvement from GE contract renegotiation.
  • Product Expansion & Operational Efficiency: New ostomy product accreditations (e.g., Defender Boot) and 19% operating cash flow increase to $24.4M in FY2025.

Operational Highlights and Guidance

The company's Patient Services segment is expected to drive growth in 2026, with net revenue projected to increase by 6% to 8% on a pro forma basis. The adjusted EBITDA margin is expected to remain in the mid- to low 20% range. Key initiatives, including the migration of the Wound Care business to a new revenue cycle application and the addition of new accreditations for home healthcare DME products, are expected to accelerate growth. As Carrie Lachance noted, the revenue cycle system has been helpful in driving reduction in lead times and has allowed the company to take on more volume and ramp in a more productive way.

Valuation and Outlook

InfuSystem Holdings' valuation metrics suggest a reasonable price for the company's growth prospects. The P/E Ratio stands at 19.51, while the EV/EBITDA ratio is 7.37. The company's Return on Equity (ROE) is 17.17%, indicating a strong ability to generate returns for shareholders. With analysts estimating revenue growth at 7.3% for next year, the company's prospects appear bright. The expected reduction in expenses related to the ERP project, with annualized savings of around $2 million, is an added positive. Overall, InfuSystem Holdings' solid FY25 results and promising outlook suggest that the company is well-positioned for continued growth.

Balance Sheet and Cash Flow

InfuSystem Holdings' balance sheet remains healthy, with available liquidity totaling nearly $58 million as of December 31, 2025. The company's debt consists of $20 million in borrowings on its revolving line of credit, which expires in July 2030. The net debt to EBITDA ratio is a comfortable 0.01, indicating a low level of indebtedness. The company's capital allocation priorities remain focused on paying down debt, share buyback, and investing in the business, providing a framework for future growth.

3. NewsRoom

Card image cap

InfuSystem Holdings, Inc. (INFU) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

InfuSystems Holdings, Inc. (INFU) Q4 Earnings Beat Estimates

Feb -24

Source: zacks.com

Card image cap

InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025

Feb -24

Source: businesswire.com

Card image cap

InfuSystem to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb -17

Source: businesswire.com

Card image cap

InfuSystem: Regulatory Backed Market Catalyst

Jan -30

Source: seekingalpha.com

Card image cap

Head to Head Analysis: SANUWAVE Health (OTCMKTS:SNWV) & InfuSystem (NYSE:INFU)

Dec -26

Source: defenseworld.net

Card image cap

AWM Investment Company Inc. Cuts Position in InfuSystem Holdings, Inc. $INFU

Dec -13

Source: defenseworld.net

Card image cap

Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026

Dec -10

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.78%)

6. Segments

Patient Services

Expected Growth: 7%

InfuSystem Holdings, Inc.'s 7% growth in Patient Services is driven by increasing demand for ambulatory infusion services, expansion into new markets, and strategic partnerships with healthcare providers. Additionally, the company's focus on improving patient outcomes and reducing healthcare costs through its proprietary technology and clinical expertise contributes to its growth.

Device Solutions

Expected Growth: 9%

InfuSystem Holdings' Device Solutions segment growth is driven by increasing demand for portable infusion devices, expansion into new markets, and strategic partnerships. The company's focus on rental and sales of infusion pumps, as well as its comprehensive service offerings, contribute to its growth. Additionally, the rising need for ambulatory infusion therapy and home healthcare services further fuels the segment's growth.

7. Detailed Products

Infusion Pumps

Portable medical devices that deliver fluids, medications, and nutrients to patients in a controlled manner

Pump Management Services

Comprehensive management of infusion pumps, including maintenance, repair, and replacement

Biologics and Pharmaceuticals

Specialty pharmaceuticals and biologics used to treat various diseases and conditions, such as cancer, rheumatoid arthritis, and multiple sclerosis

Nursing Services

Skilled nursing services provided in patients' homes, clinics, or hospitals, including infusion therapy and medication management

Durable Medical Equipment (DME)

Medical equipment and supplies used in the home or clinical settings, such as wheelchairs, hospital beds, and oxygen therapy equipment

8. InfuSystem Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for InfuSystem Holdings, Inc. is medium due to the presence of alternative medical equipment and services that can replace the company's offerings.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of InfuSystem Holdings, Inc.'s medical equipment and services, which limits customers' ability to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium due to the presence of multiple suppliers of medical equipment and services, which gives InfuSystem Holdings, Inc. some negotiating power.

Threat Of New Entrants

The threat of new entrants is high due to the relatively low barriers to entry in the medical equipment and services industry, which makes it easier for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established companies in the medical equipment and services industry, which leads to intense competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 36.89%
Debt Cost 10.42%
Equity Weight 63.11%
Equity Cost 10.42%
WACC 10.42%
Leverage 58.46%

11. Quality Control: InfuSystem Holdings, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
InfuSystem Holdings

A-Score: 4.3/10

Value: 4.3

Growth: 5.7

Quality: 5.7

Yield: 0.0

Momentum: 7.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
STAAR Surgical

A-Score: 3.9/10

Value: 6.8

Growth: 4.1

Quality: 4.8

Yield: 0.0

Momentum: 5.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Atrion

A-Score: 3.6/10

Value: 3.6

Growth: 3.0

Quality: 6.2

Yield: 1.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
NEXGEL

A-Score: 3.1/10

Value: 7.9

Growth: 4.9

Quality: 4.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Femasys

A-Score: 2.8/10

Value: 6.2

Growth: 2.8

Quality: 3.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Harvard Bioscience

A-Score: 2.2/10

Value: 8.4

Growth: 1.1

Quality: 2.8

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.18$

Current Price

9.18$

Potential

-0.00%

Expected Cash-Flows